Clinical Study
Improving Safety of Preemptive Therapy with Oral Valganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
Table 2
Patient cohorts of preemptive therapy for CMV viremias.
| | Cohort 1 (1996–2006) | Cohort 2 (2007–2011) | | VGC | Non-VGC | P | VGC | Non-VGC | P |
| N patients | 79 | 90 | — | 48 | 70 | — | N viremias | 165 | 147 | — | 67 | 135 | — | Gender | | | | | | | Female | .44 | .44 | n.s. | .50 | .47 | n.s. | Male | .56 | .56 | .50 | .53 | Age | | | | | | | Median | 50 | 43 | <0.001 | 53 | 56 | n.s. | Range | 18–68 | 18–65 | | 20–67 | 19–72 | | Diagnosis | | | | | | | Nonmalignant | .03 | .00 | n.s. | .03 | .04 | n.s. | Chronic malignancy | .24 | .26 | .17 | .32 | Acute malignancy | .73 | .74 | .80 | .64 | Disease risk | | | | | | | Standard | .29 | .47 | <0.05 | .11 | .23 | n.s. | Advanced | .71 | .53 | .89 | .77 | Donor | | | | | | | Matched related | .28 | .43 | n.s. | .25 | .21 | n.s. | Matched unrelated | .68 | .52 | .44 | .53 | Mismatched | .04 | .05 | .31 | .26 | CMV | | | | | | | R−/D−, R−/D+, R+/D+ | .51 | .67 | <0.05 | .69 | .70 | n.s. | R+/D− | .49 | .33 | .31 | .30 | Conditioning | | | | | | | Reduced intensity | .65 | .30 | <0.001 | .83 | .79 | n.s. | Myeloablative | .35 | .70 | .17 | .21 | T cell depletion | | | | | | | None | .11 | .40 | | .06 | .08 | n.s. | In vivo (ATG) | .84 | .44 | <0.001 | .94 | .92 | In vitro | .05 | .16 | | .00 | .00 |
|
|